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Heterogeneous Biologics Pipeline 
Monoclonal Antibody (mAb) 
~150,000 Da 
Growth Factors & Cytokines 
 ~ 15 -25,000 Daltons 




Insulin- MW ~5800 Da 
Bispecific
Ag1 Ag2
Peptides- MW ~22,000 Da 
Improving Biologics via Innovative Solutions 
Requirements Benefits Solution Examples 
Single Use Technologies  
PAT 
Tools 
Synchronized Supply Chain  
Enables Innovation  
continuum  
Predictive / 
 Adaptive Control   
Real time 
 release  





Plug & play capability 
Closed processing  
CIP/SIP removed  
Intensive low volume processes  
(<2KL) 
Expand via scale out 
NOT scale up  
First in Class Pipeline  
Biologics & Vaccines 
Agility & flexibility to adapt to change via toolbox 
of intensive platform & facility  options  
High throughput & low cost technologies for new 
business growth & drive down costs 
Robust processes with predictive / adaptive control 
& improved assurance of quality  
Integrated/continuous platforms for responsive  
synchronized supply chain using modular 
Facilities of the Future 
Flexibility to meet varying demands 
Low capital cost 
Rapid turnaround increasing capacity  to support 
the pipeline 
Increased sterility assurance 
On demand production 
Reduced Inventory costs  
Portable capacity for local or regional capacity 
Improved assurance of quality 
reducing deviations/failures 
Multi product capable facilities 
Small low cost  footprint 
Expansion via Scale Out 
Rapid construction 
Continuous Adaptive Bioprocessing:  
PAT, Automated Control & Real Time Release 












Process &  
Product Quality  
Data 
Multivariant Model  
Data Historian  
Feed Forward &  
Feedback Control 











Real Time Release 
PAT Tools 





Enabling Technologies for Real Time Analytics: 





















































• Developed for integration into continuous processing 
• Deployable into current batch processes 
RTMW with LS 




























































































Current State: Analytical Assays for DS & DP 
7 
• Appearance 
• Clarity and opalescence 
• Color 
• Visible particles 
• Particulate matter 
• Reconstitution time (DP lyo ) 
• Residual moisture content (DP lyo) 
• Binding ELISA 
• Charge distribution (HP-IEX) 
• Peptide Map (digestion+LC) 
• Cell-based binding assay 
• Protein Concentration (UV) 
• IgG SEC (HP-SEC) 
• IgG intact  (CE-SDS-NR) 
• IgG reduced (CE-SDS-NR) 
• Residual DNA (DS only) 
• Residual HCP (DS only) 
• Residual Protein A (DS only) 
• Excipients (LC-CAD) 
• Osmolality 
• pH 
• Bacterial endotoxins 
• Bioburden (DS only) 
• Sterility (DP only  15 day assay) 
• Container closure integrity test (DP only) 
• Extractable volume (DP only) 
 
21 DS Assays and 22 DP Assays 
17 Common Assays 
 
Future Opportunities: Reduce Common DS/DP Analytical Assays 
Shop Floor (At/On-Line) 
• Appearance 
• Clarity and opalescence 
• Color 
• Visible particles 
• Particulate matter 
• Protein concentration (UV) 
• IgG SEC (HP-SEC) 
• Osmolality 
• pH 
• Bacterial endotoxins 
• Excipients (LC-CAD) 
QC Lab (Relative Potency) 
• Binding ELISA 
• Cell-based binding assay 
• Reduced IgG  (rCE-SDS) 
• Peptide map (Identity) 




• Oxidation (HIC) 
• HCP (ELISA) 
• Pro A (ELISA) 
• N-glycan (iAB) 
Reduced Peptide Mapping LC-MS (MAM) 
Drug Product:  
Adaptive filling for flexible & agile capacity 
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Current Drug Product Operations 
 
Single-use bag and holder 
• Capital intensive 
• High volumes to be cost effective 
• Large, rigid infrastructure 
• Longer changeovers 
• Accepts multiple images & products  
• Flexible batch sizes  
• Capital & OpEx reduction 
• Shorter changeovers 
Flexible Adaptive Filling Operations 
Adaptive 
vial / syringe filler 
Future State Platform Toolbox:  
Flexible capacity to meet varying demand, pipeline needs 
10 
Sequential Batch Processing  
Rapid, high-throughput development 
CMO-ready 
Fed-Batch 
2,000 – 20,000 L scale 
Continuous Processing 
Longer, more intensive development 
Internal capacity or select CMOs 
Perfusion 







Decision framework to be developed to 
trigger which programs developed for 
intensive platform, and at what stage of 
development 
CASE STUDY 1:   
 
ANALYTICS FOR PROCESS MONITORING 
11 
Multi-Attribute Method for Process Monitoring 
Experimental Design 
12 
1) Replace feed material from online 
bioreactor with feed from 2nd perfusion 
tank 
2) Measure response in titer and quality 
throughout system 
3) Product quality attributes monitored with 
reduced peptide mapping LC-MS (MAM) 
4) Determine characteristic residence time 
















Feed Material (c1, CQA1) 
Perfusion 1 
Feed Material (c0, CQA0) 

























PAP VIP FVIP AEXP






























PAP VIP FVIP AEX
Other MAM Data 
N-terminal Pyroglutamate Oxidation Site 
• Multiple quality 
attribute detected & 
demonstrated 
material tractability 
• Low throughput 
method 
• Efforts underway to 
cut runtime for better 
alignment with 
process timescales 
Real-time molecular weight via light scattering 
• In-line measurement (near real time <15s) 
• Process Control: Trigger fraction collection when 
molecular weight meets a preset condition 
• Integrated within existing unit operations (i.e. peak 
cutting) or as a monitor after a unit operation (i.e. DS) 
UV 
Real Time MW 
Triggers from MALS to AKTA 






















































Bind and Elute 
Flow Through 
CASE STUDY 2:   
 
TUNABLE PROTEIN PRODUCTION 
15 
Continuous Downstream Operation 
Process control for flexible drug supply  
16 
Perfusion feed rate increase to double kg output 
Feed rate change 
Minimal impact to purity & quality 
Output 
(kg) 
30 MM cells/mL 
1VVD 
60 MM cells/mL 
2VVD 






































































CASE STUDY 3:   
 
IMPACT OF DIRECT FILLING ON SUPPLY CHAIN 
17 
1. Single product facilities 
2. Facility types 
• 1 x 12500L SS 5g/L Batch USP / Batch DSP (670kg/year basis)  
• 6 x 2000L SU 5g/L Batch USP / Batch DSP 
• 2 x 1700L SU 20g/L Batch USP / Continuous DSP 
• 2 x 1200L SU 3g/L Continuous USP Continuous DSP 
3. Three column baseline process 
4. Continuous DSP lines have adaptive direct filling capabilities 
• Continuous DSP lines utilise pull model 
• Batch DSP lines utilize push model 
5. Discrete event modeler (Extend Sim 9) to simulate demand and trigger production batches 
• Bulk API and DP dynamic stocking profiles 
• Product Lifecycle 
• Tracks an individual batches moving through the system 
6. Stock Storage Cost (Estimated) 
• DS 5$/g/month 
• DP 10$/g/month 
 
18 
DS & DP Supply Chain - Assumptions 
19 













DP Stock Sales 
Push 
Pull 
• A prediction of the number of batches required is made 
on a defined look ahead, e.g. 12 months of sales 
• The batches for those 12 months are scheduled to be 
produced 
• If the sales changes after a campaign is ordered then it 
cannot be changed 
• Held stock level is typically higher due to the not being 
able to respond to changes in sales 
• Easier to run in a multiproduct facility 
• Orders are sent through to match the target level 
• Once above the target level then orders stop and sales 
will reduce the level until it is below the target and more 
are then ordered 
• Responds much better to changes in sales, as the 
number/frequency of batches can be changed 
• Can manage lower inventory levels due to the more 
rapid response to change 
• Typically requires dedicated a facility  
20 
Drug Product Inventory Modelling 
• Combination graph of the DP 
Inventory levels with the Sales and 
Target DP level 
• The plots have been averaged on a 
monthly basis from the raw data 
• The 1x12,500L SS and 6x2,000L 
SU are identical plots and are 
shown on the same line in grey 
Cost of Inventory 
21 
• Smaller Facilities = Less Product per Batch  
• Reducing peak and variance of stock in relation to demand 
• Pull Schedules compared to Push Schedules 
• Lower stock variation produce based on demand 
• Demand planning horizon based on lag time in line 
• Pull schedules not easy in multi product facility 
• Push Schedules 
• Based on 12 month forecast (can be 18months out of date) 
• Less responsive to demand 
• Higher safety stocks required 
CONCLUSIONS 
22 
Transitioning to Next Generation Bioprocessing 









Assurance of  
Quality  
Traditional Production 
Disconnected Batch Processing 
Stainless Steel, Separate DS & DP  
Traditional QC release 
Integrated Semi Continuous 
Integrated DS & DP ,  Basic PAT  
Rapid QC release 
Automated Continuous  
Processing DS & DP 
Adaptive Control & Advd PAT  
Real time QC release 
Single Use Batch Processing  
Time to GMP  Readiness 
 
Integrated Semi Continuous 
Single Use Batch Processing 
Toolbox of Flexible  
Lower Cost Options  
Begin integration  
and inline PAT  
Complete integration 
& real time release 
Conclusions 
24 
• Continued development on a toolbox of processing platforms  
• Flexible ‘plug and play’ single use technologies  
• Continuous production with integrated QbD, IT, PAT, & QA Tools                        
• Enabling adaptive attribute control with real time release 
• Driving to : 
• Small modular agile facilities with embedded sustainability 
• Responsive synchronized value chain  for adaptive clinical & 
commercial production with global reach continuum 
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Continuous Processing Vision - 2,000L SUB* 
Overall DSP Time Cycle is Dictated by the Longest Step 
































Single-Use Surge Vessel 
BRF 
BRF 
HC 
DS 
